Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

NCT04305041 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Quavonlimab
BIOLOGICAL: Vibostolimab
DRUG: Lenvatinib
DRUG: ATRA

Sponsor

Merck Sharp & Dohme LLC